2023-05-09 08:57:22 ET
- HCW Biologics press release ( NASDAQ: HCWB ): Q1 GAAP EPS of -$0.14 beats by $0.02 .
- Revenue of $0.01M (-99.4% Y/Y).
- As disclosed above, the Company entered into a development line of credit agreement for the buildout of the Company’s new headquarters and manufacturing facility. Funds formerly earmarked for this purpose will be redeployed for clinical development. The Company estimates that the cash and cash equivalents, short-term investments and the proceeds of the development line of credit extends the Company’s cash runway into 2025.
For further details see:
HCW Biologics GAAP EPS of -$0.14 beats by $0.02, revenue of $0.01M